Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 21,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Peripheral Neuropathy
Interventions: Tai Chi/Qi Gong, α- Lipoic acid, Acupuncture; Behavioral · Dietary Supplement · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Behavior, Health
Interventions: Pre-visit and post-visit patient messaging, Default pended order, EHR communication; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 16,416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasm Metastasis, Cancer, Radiation Therapy Complication
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Ronald McGarry; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions: HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more

Conditions: Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clinically Severe Obesity, Metabolic Complications After Jejunoileal Bypass, Nutritional Complications After Jejunoileal Bypass, Obesity Recidivism, Inadequate Initial Weight Loss, Intestinal Malabsorptive Syndrome, Protein Malnutrition
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Opioid Prescribing, Prescription Drug Misuse
Interventions: PDMP Legal Mandate E-mail, PDMP Clinical Benefit E-mail; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 7,872 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Pre-diabetes
Interventions: (+)-Epicatechin; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 21 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Depressive Symptoms, Anxiety Disorders and Symptoms, Behavioral Symptoms, Ethnic-Racial Socialization
Interventions: One Talk at a Time: Race, One Talk at a Time: General; Other
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: Not listed
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Depressive Symptoms, Caregiver Burden
Interventions: Morning Action Plan Execution, Activity Strategy-based Session with Therapist, Attention-based Session with Therapist, Advance sleep-wake time; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Spinal Cord Injuries
Interventions: Biofeedback; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fetal Growth Retardation
Interventions: Ferumoxytol infusion, MRI scan; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alcohol Drinking, Weight Loss, Adiposity, Obesity, Visceral Obesity
Interventions: Alcohol, No Alcohol; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Interventions: anito-cel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 10 more

Conditions: Social Media, Digital Well-being
Interventions: Friction-Based Smartphone Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate); Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more

Conditions: Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions: Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Marfan Syndrome
Interventions: Blood draw; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Months to 24 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gestational Diabetes, Controlled by Diet
Interventions: Fingerstick; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy; Seizure
Interventions: Oral 2-Deoxy-D-Glucose (2DG); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colonic Neoplasms
Interventions: Normal (0.9%) saline, HalfLytely; Drug
Lead sponsor: Arya, Vijaypal, M.D., P.C.; Individual
Eligibility: 21 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Middle Village, New York

Conditions: Nicotine Dependence, Tobacco Smoking
Interventions: Normal Nicotine Control Group, Immediate Nicotine Reduction Group, Gradual Nicotine Reduction Group; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Phoenix, Arizona • San Francisco, California • Tampa, Florida + 7 more

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sleep Apnea, Obstructive
Interventions: Placebo pill, Trazodone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study

Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters

Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

STOP Heart Disease in Breast Cancer Survivors Trial

Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass

E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

One Talk at a Time: A Racial-ethnic Socialization Intervention for Diverse Families

Caregiver Stress and Sleep Study

Biofeedback for Wheelchair Users

Placental Lesions in Fetal Growth Restrictions

The Effects of Alcohol Consumption on Central Adiposity

Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases

Digital Habit Interventions

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

Glucose Frequent of A1GDM in Labor

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

Project 2: Strategies for Reducing Nicotine Content in Cigarettes

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

The Effects of Trazodone on Sleep Apnea Severity